This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medical-Device ETF in the Spotlight

NEW YORK ( ETF Expert) -- Price-to-earnings (P/E) ratios have been rising over the course of the four-and-a-half year bull market. It follows that there are fewer and fewer bargains. Indeed, a quick screen at Morningstar reveals a dwindling universe of stocks with torward P/Es that are lower than their respective five year averages.

Similarly, Morningstar is relatively stingy when it comes to handing out four or more stars on the ratings of individual securities. Thousands of stocks may be up for consideration. Right now, though, fewer than 200 make the cut.

When you combine the two criteria, one sub-sector has a large percentage of its total universe in the mix. Even more striking, this sub-segment that appears to stand apart has been widely covered in the media throughout the government shutdown. The industry? Medical devices and equipment.

Equipment makers/suppliers such as Medtronic (MED), Covidien (COV), Baxter (BAX) as well as Abbott Laboratories (ABT) all showed up in the screening. Their respective prices are quite far from recent highs, in part because of the uproar over the probable implementation of the Affordable Health Care Act's 2.3% tax on medical devices corporations.

Nearly all Republicans oppose the unpopular tax, while a large chunk of Democrats want to see the tax removed from the law as well. Democrats, however, want to replace the potential $30 billion in tax revenue before signing off on repealing the medical devices tax.

At the moment, few Democrats have indicated they would cross the current party line; that is, until the GOP in the House passes an unencumbered bill to fund government operations, and until the same Republicans agree to raise the debt ceiling without preconditions, there will be no negotiations. Indeed, medical device providers may have to pick up part of the tab for universal health care after all.

Regardless, iShares Medical Devices (ITI) remains in a bona fide uptrend. The exchange-traded asset has received support near a shorter-term, 50-day moving average throughout the year. Moreover, the current price is above both a 50-day as well as a 200-day trendline, sitting not far from an all-time peak.

Courtesy of

Whereas shares of some of the component corporations have taken a beating, this diversified vehicle still remains popular. Perhaps a deal to vanquish the medical device tax would make the asset even more attractive to would-be buyers.

Then again, there is no telling how long it will take for partisan politics to run its course. IHI would not be immune to panicky selling should stock investors start stampeding for the exit door.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Disclosure Statement: ETF Expert is a website that makes the world of ETFs easier to understand. Gary Gordon, Pacific Park Financial and/or its clients may hold positions in ETFs, mutual funds and investment assets mentioned. The commentary does not constitute individualized investment advice. The opinions offered are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial or its subsidiaries for advertising at the ETF Expert website. ETF Expert content is created independently of any advertising relationships. You may review additional ETF Expert at the site.

Gary Gordon reads:

Real Clear Markets
Jeff Miller
Charles Kirk
On Twitter, Gary Gordon follows:

Jonathan Hoenig
Doug Kass
Hard Assets Investor

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs